
Key Points
- 01CVS Health study finds GLP-1 users see better outcomes and lower hospital use
- 02Current GLP-1 prices do not yet deliver financial break-even for plan sponsors
- 03Employers may break even if GLP-1 weight-loss drugs are priced below $350 a month
- 04Three-year analysis shows $9,400 in medical savings but $13,300 higher drug spend
CVS identifies break-even price point for GLP-1 drugs
CVS Health has determined that employers could reach a financial break-even point on GLP-1 weight-loss medications if prices drop below $350 per month. The conclusion comes from an internal analysis of claims data that compared the medical savings generated by GLP-1 use with the higher pharmacy spending associated with the drugs. At current prices, the study finds that the additional prescription costs still outweigh the medical savings, meaning the medicines do not yet pay for themselves for health plan sponsors.
GLP-1 therapies were originally developed for type 2 diabetes and now have approved uses across obesity and cardiovascular, liver and kidney disease. CVS Health notes that more than 137 million U.S. adults are medically eligible for semaglutide across these indications, with many qualifying under more than one. As eligibility and demand expand, the question of whether these medicines can be made affordable at scale has become more urgent for employers and health plans.
Study design and real-world outcomes
The CVS Health research uses anonymized Aetna claims data from commercial fully insured members, with index years from 2023 through 2025 and up to three years of follow-up. GLP-1 users were matched with similar non-users based on age, existing health conditions, prior health care use and baseline medical and pharmacy spending. This matching approach was designed to isolate the impact of GLP-1 treatment on health outcomes and costs in routine clinical practice.
The analysis found that GLP-1 use was associated with better clinical outcomes, lower hospital use and lower medical spending compared with matched non-users. Over a three-year period, medical bills dropped by $9,400 per person among GLP-1 users. At the same time, prescription spending increased by $13,300 per person, leaving a net cost increase of $3,900 per patient for plan sponsors. These results illustrate that, while the medicines deliver meaningful clinical benefits, current pricing prevents full offset of their cost through reduced medical utilization.
Affordability challenge and adherence factors
CVS Health emphasizes that GLP-1s are highly effective medicines and that the health benefits are real, but it highlights the challenge of making those benefits affordable for broad populations. The study also examined whether staying on treatment mattered, comparing all patients who started a GLP-1 with those whose prescriptions covered at least 80% of days during follow-up, a standard measure of medication adherence. The findings support a focus on getting treatment to people most likely to benefit and helping them remain on therapy to maximize value.
CVS Health’s chief medical officer, Amy Compton-Phillips, notes that higher-risk patients can reach a return on investment more quickly, underscoring how patient selection influences financial outcomes. She points to current direct-to-consumer cash prices for GLP-1 medicines, which range from $299 to $349 per month, as evidence that lower prices for employers may be feasible while maintaining manufacturer profitability. CVS Health also stresses that financial break-even should not be the sole measure of a medicine’s value, and it has published a white paper titled “GLP-1s: Good Drugs, High Prices” to outline the trade-offs facing payers.
Key Takeaways
- 01GLP-1 therapies improve outcomes and reduce hospital and medical spending, but current pricing still leads to higher overall costs for employers.
- 02A sub-$350 monthly price point is identified as a potential threshold where GLP-1 weight-loss drugs could break even financially for health plans.
- 03Rising eligibility for semaglutide and the influence of adherence and patient risk level make pricing and access strategies central to GLP-1 adoption.
References
- https://finance.yahoo.com/healthcare/articles/cvs-sees-possible-break-even-151108349.html?.tsrc=rss
- https://investors.cvshealth.com/news/news-details/2026/CVS-Health-study-highlights-GLP-1-benefits-and-the-affordability-challenge/default.aspx
- https://www.cvshealth.com/news/company-news/cvs-health-study-highlights-glp-1-benefits-and-the-affordability-challenge.html
- https://www.archynewsy.com/cvs-glp-1-drugs-save-money-below-350-month/